Key Botulinum Toxin Brands

Botox®

Neuronox®

Dysport®

Botox® (onabotulinumtoxinA) is The first commercially developed and approved botulinum toxin product, and widely considered the reference standard among botulinum toxin type A products, supported by the longest clinical history and the most extensive evidence base.

Decades of clinical research have evaluated its efficacy, safety, and long-term treatment outcomes across multiple approved aesthetic and therapeutic applications.

Key differentiator: First-in-class, reference product, most extensive clinical evidence.

Neuronox® have demonstrated clinical efficacy and safety comparable to established botulinum toxin products when administered using appropriate dosing and injection techniques.

It has been widely used in Asia with an expanding body of clinical evidence.

Published studies have reported clinical outcomes for Neuronox in specific aesthetic and therapeutic indications. See Neuronox Clinical Evidence for study-specific findings.

Key differentiator: Long clinical experience in Asian markets with established efficacy and safety.

Dysport® (abobotulinumtoxinA) has demonstrated consistent efficacy and safety across aesthetic and therapeutic indications.

Studies of Dysport have reported differences in field of effect under specific dosing and study conditions; these findings should not be generalized across indications.

Key differentiator: Broader field of effect (in some settings); well established in both aesthetic and therapeutic use.

Explore the distinct characteristics of leading Botulinum Toxin products, focusing on their scientific specifications and clinical evidence.

Xeomin®

Xeomin® is a highly purified botulinum toxin type A containing no accessory (complexing) proteins. This purified formulation provides efficacy and safety comparable to established products while minimizing unnecessary bacterial proteins.

Key differentiator: Free from complexing proteins (naked neurotoxin), while minimizing exposure to unnecessary bacterial proteins.

*The highly purified formulation may reduce antigenic protein exposure; however, the clinical significance regarding immunogenicity remains under investigation.

Nabota®

Nabota® (prabotulinumtoxinA) is manufactured using a high-purity production process and has demonstrated efficacy and safety comparable to established botulinum toxin type A products. It is approved for both aesthetic and therapeutic indications in multiple countries.

Key differentiator: High-purity formulation with growing international clinical evidence.

Diffusion / Spread Profile of Botulinum Toxin Type A Products

Conclusions from the Evidence

Overall, no commercially available botulinum toxin type A product has been consistently shown to diffuse more or less than others under equivalent clinical conditions.

Product selection should therefore be based on the following points :

• approved indication

• physician experience

• treatment objectives

rather than assumptions regarding diffusion characteristics.

Based on the available evidence:

• Dysport® (abobotulinumtoxinA): May exhibit a slightly broader field of effect in some clinical settings, although this difference becomes minimal when equivalent dosing and appropriate conversion ratios are used.

• Botox® (onabotulinumtoxinA): Demonstrates a predictable diffusion profile and serves as the reference standard with the largest body of clinical evidence.

• Xeomin® (incobotulinumtoxinA): Clinical studies have not demonstrated a clinically significant difference in diffusion compared with Botox®.

• Nabota® (prabotulinumtoxinA): Current evidence does not demonstrate a clinically meaningful difference in diffusion compared with established botulinum toxin type A products.

• Neuronox®: Available clinical evidence does not support a significant difference in diffusion relative to other commercially available botulinum toxin type A products.

• Current evidence does not support a definitive ranking of botulinum toxin type A products based on diffusion or spread.

• Clinical studies and systematic reviews indicate that diffusion is influenced more by dose, dilution, injection volume, injection technique, and patient-specific anatomy than by the product itself.

Immunogenicity: Long-term Efficacy

Access the latest peer-reviewed consensus statements and clinical guidelines on neutralizing antibodies and resistance.

• COMPLETE SITE INDEX

Access all clinical evidence methodologies, facial anatomy maps, brand comparison data, and editorial standards currently published across the BotoxWiki platform.

Clinical & Anatomy

Evidence & Review

Editorial & Trust

Reference Standard

BotoxWiki provides evidence-based content, medical review, and a neutral editorial approach to botulinum toxin formulations and anatomical guidance.

© BotoxWiki Clinical Reference Directory.

All anatomical models, literature reviews, and evidence summaries are strictly peer-reviewed and non-commercial.